A systematic review found an association between prescribed benzodiazepines and suicidal behaviors, while leaving causal direction and individual attribution unresolved.
Twenty-one studies were included, with a pooled effect estimate of 2.74 and a 95% confidence interval of 2.06–3.63. The evidence considered attempted and completed suicide outcomes. The authors discussed possible behavioral mechanisms and the need for better longitudinal evidence, as well as gaps concerning exposure patterns and other substances.
People prescribed benzodiazepines can already have anxiety, insomnia, depression, crises or other risk factors. Pooling does not remove confounding by indication, reverse causation or differences in outcome definitions. The estimate should not be presented as a universal absolute risk, a drug-specific probability or proof of a causal mechanism.
For a retrospective opinion, reconstruct symptoms and suicidal thinking before and after treatment, concurrent substances and the medication timeline. A population association can inform a differential assessment but cannot show that one prescription created intent or that absence of that prescription would have prevented an individual death.
Source reviewed: Prescribed benzodiazepines and suicidal behaviors a systematic review meta analysis and clinical imp (PMC13072626). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Ketamine Suicidality Trials Used Midazolam as an Active Comparator.